Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial
February 2021
in “
Cureus
”
Studysummary In this study, Proxalutamide significantly increased the rate of viral clearance and reduced clinical remission time in patients with mild to moderate COVID-19 compared to placebo.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on assets.cureus.com →